Israeli millionaires drop by 28 percent

Israel now has 5,900 high-net-worth individuals, defined as those with at least $1 million in liquid financial assets.

By JTA
June 30, 2009 10:16

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The number of Israeli millionaires has fallen by 28 percent, nearly twice the global total. According to the Merrill Lynch World Wealth report released June 25, Israel now has 5,900 high-net-worth individuals, defined as those with at least $1 million in liquid financial assets, down 2,300 from the 2008 report. The number of global millionaires fell by 14.9%, according to the report. In the United States, the number dropped by 18.5%. Hong Kong lost the most millionaires, 61%, from the previous year. According to the report, the number of Israeli "ultra-high-net-worth individuals," with liquid assets of at least $30m., fell by 24.6%, from 97 to 73.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS